Acute and Postacute Clinical Characteristics of Coronavirus Disease 2019 in Children in Japan. Issue 3 (30th November 2022)

• Record Type: Journal Article
• Authors: Katsuta, Tomohiro; Aizawa, Yuta; Shoji, Kensuke; Shimizu, Naoki; Okada, Kenji; Nakano, Takashi; Kamiya, Hajime; Amo, Kiyoko; Ishiwada, Naruhiko; Iwata, Satoshi; Oshiro, Makoto; Okabe, Nobuhiko; Korematsu, Seigo; Suga, Shigeru; Tsugawa, Takeshi; Nishimura, Naoko; Hishiki, Haruka; Fujioka, Masashi; Hosoya, Mitsuaki; Mizuno, Yumi; Miyairi, Isao; Miyazaki, Chiaki; Morishima, Tsuneo; Yoshikawa, Tetsushi; Wada, Taizo; Ouchi, Kazunobu; Moriuchi, Hiroyuki; Tanaka-Taya, Keiko; Saitoh, Akihiko
• Is Part Of: Pediatric infectious disease journal. Volume 42:Issue 3(2023)
• Page Start: 240
• Page End: 246
• Publication Date: 2022-11-30
• Subjects: COVID-19 -- pediatrics -- clinical characteristics -- severity -- postacute; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000003792
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Background: The clinical features of coronavirus disease 2019 (COVID-19) in children have been changing because of the emergence and rapid spread of variants of concern (VOC). The increase in cases infected with VOC has brought concern with persistent symptoms after COVID-19 in children. This survey aimed to analyze the clinical manifestations and persistent symptoms of pediatric COVID-19 cases in Japan. Methods: We analyzed the clinical manifestations of pediatric COVID-19 cases reported between February 2020 and April 2022 in Japan, using a dedicated database updated voluntarily by the members of the Japan Pediatric Society. Using the same database, we also analyzed persistent symptoms after COVID-19 in children who were diagnosed between February 2020 and November 2021. Results: A total of 5411 and 1697 pediatric COVID-19 cases were included for analyzing clinical manifestations and persistent symptoms, respectively. During the Omicron variant predominant period, the percentage of patients with seizures increased to 13.4% and 7.4% in patient groups 1–4 and 5–11 years of age, respectively, compared with the pre-Delta (1.3%, 0.4%) or Delta period (3.1%, 0.0%). Persistent and present symptoms after 28 days of COVID-19 onset were reported in 55 (3.2%). Conclusions: Our survey showed that the rate of symptomatic pediatric COVID-19 cases increased gradually, especially during the Omicron variant predominant period, and a certain percentage of pediatric cases had persistent symptoms. Certain percentages of pediatric COVID-19 patients had severe complications or prolonged symptoms. Further studies are needed to follow such patients.